Alterations in B-cell Subsets and Clinical Predictors of Response to Telitacicept in Antiphospholipid Antibody-Positive SLE Patients: A Prospective Observational Study - Takeaways - MDSpire

Alterations in B-cell Subsets and Clinical Predictors of Response to Telitacicept in Antiphospholipid Antibody-Positive SLE Patients: A Prospective Observational Study

  • By

  • Yadi Sun

  • Xu Wang

  • Yueying Wang

  • Ping An

  • Dazhen Guo

  • Qian Xing

  • April 23, 2026

  • 0 min

Share

  • 1

    Telitacicept treatment in aPL-positive SLE patients significantly reduced double-negative B cells and plasmablasts over 24 weeks.

  • 2

    65% of patients achieved an SRI-4 response at week 24, with notable improvements in SLEDAI-2K scores and other clinical parameters.

  • 3

    Higher baseline levels of IgG and anti-β2GPI IgG were identified as independent predictors of a favorable response to telitacicept.

  • 4

    Telitacicept may provide a safe and effective treatment option for patients with aPL-positive SLE by targeting B-cell dysregulation.

  • 5

    The study highlights the need for novel therapies in SLE, particularly for patients with persistent antiphospholipid antibody positivity.

Original Source(s)

Alterations in B-cell Subsets and Clinical Predictors of Response to Telitacicept in Antiphospholipid Antibody-Positive SLE Patients: A Prospective Observational Study

  • by Yadi Sun, Xu Wang, Yueying Wang, Ping An, Dazhen Guo, Qian Xing

  • April 23, 2026

Related Content

Comparative effectiveness and safety of biologics and targeted small-molecule therapies plus stable background therapy in systemic lupus erythematosus: a systematic review and network meta-analysis

EULAR Updates Behçet’s Syndrome Recommendations

EULAR releases updated recommendations supporting earlier biologic use in patients with eye, vascular, and nervous system involvement

Editorial: The role of innate immunity in the pathogenesis of autoimmune and autoinflammatory diseases